Prostate cancer detection after a negative prostate biopsy: Lessons learnt in the Cleveland Clinic experience

International Journal of Urology

Volumn 18, Issue 8, 2011, Pages 557-568

  Zaytoun, Osama M ^a,b   Jones, J Stephen ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Nomogram; Pathological findings; Prostate specific antigen; Repeat biopsy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACINAR CELL; CANCER DIAGNOSIS; CANCER GRADING; CANCER RISK; CANCER SIZE; CANCER SURGERY; CELL PROLIFERATION; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; HUMAN; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; SENSITIVITY AND SPECIFICITY;

BIOPSY, NEEDLE; FALSE NEGATIVE REACTIONS; HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS;

EID: 79960624275     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2011.02798.x     Document Type: Review

References (110)

1. Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur. Urol. 2007; 52: 1309-22.
2. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J. Urol. 2002; 167: 2435-9.
3. Fleshner NE, O'Sullivan M, Fair WR. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J. Urol. 1997; 158: 505-8.
4. Terris MK. Strategies for repeat prostate biopsies. Curr. Urol. Rep. 2009; 10: 172-8.
5. Yanke BV, Salzhauer EW, Colon I. Is race a positive predictor of cancer on repeat prostate biopsy? J. Urol. 2006; 176: 1114-17.
6. Djavan B, Margreiter M. Biopsy standards for detection of prostate cancer. World J. Urol. 2007; 25: 11-17.
7. Hong YM, Lai FC, Chon CH, McNeal JE, Presti JC Jr. Impact of prior biopsy scheme on pathologic features of cancers detected on repeat biopsies. Urol. Oncol. 2004; 22: 7-10.
8. Eskicorapci SY, Guliyev F, Islamoglu E, Ergen A, Ozen H. The effect of prior biopsy scheme on prostate cancer detection for repeat biopsy population: results of the 14-core prostate biopsy technique. Int. Urol. Nephrol. 2007; 39: 189-95.
9. National Comprehensive Cancer Network. National Comprehensive. 2004.
10. Scattoni V, Maccagnano C, Zanni G etal. Is extended and saturation biopsy necessary? Int. J. Urol. 2010; 17: 432-47.
11. Wright JL, Ellis WJ. Improved prostate cancer detection with anterior apical prostate biopsies. Urol. Oncol. 2006; 24: 492-5.
12. Presti JC Jr. Prostate biopsy strategies. Nat. Clin. Pract. Urol. 2007; 4: 505-11.
13. Jones JS, Zippe CD. Rectal sensation test helps avoid pain of apical prostate biopsies. J. Urol. 2003; 170 (6 Pt 1): 2316-18.
14. Moussa AS, Meshref A, Schoenfield L etal. Importance of additional "extreme" anterior apical needle biopsies in the initial detection of prostate cancer. Urology 2010; 75: 1034-9.
15. Djavan B. Prostate biopsies and Vienna Nomograms. Eur. Urol. Suppl. 2006; 5: 500-10.
16. Patel AR, Jones JS, Rabets J, DeOreo G, Zippe CD. Parasagittal biopsies add minimal information in repeat saturation prostate biopsy. Urology 2004; 63: 87-9.
17. Ito K, Ohi M, Yamamoto T etal. The diagnostic accuracy of the age-adjusted and prostate volume-adjusted biopsy method in males with prostate specific antigen levels of 4.1-10.0ng/mL. Cancer 2002; 95: 2112-19.
18. Kakehi Y, S N. Japanese Urological Association. Complication rates of ultrasound-guided prostate biopsy: a nation-wide survey in Japan. Int. J. Urol. 2008; 15: 319-21.
19. Chun FK, Epstein JI, Ficarra V etal. Optimizing performance and interpretation of prostate biopsy: a critical analysis of the Literature. Eur. Urol. 2010; 58: 851-64.
20. Jones JS, Patel A, Schoenfield L, Rabets JC, Zippe CD, Magi-Galluzzi C. Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. J. Urol. 2006; 175: 485-8.
21. Lane BR, Zippe CD, Abouassaly R, Schoenfield L, Magi-Galluzzi C, Jones JS. Saturation technique does not decrease cancer detection during follow up after initial prostate biopsy. J. Urol. 2008; 179: 1746-50.
22. Marks LS, Fradet Y, Deras IL etal. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007; 69: 532-5.
23. Thompson IM, Tangen CM, Ankerst DP etal. The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy. J. Urol. 2008; 180: 544-7.
24. Djavan B, Remzi M, Schulman CC, Marberger M, Zlotta AR. Repeat prostate biopsy: who, how and when? A review. Eur. Urol. 2002; 42: 93-103.
25. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6ng/mL to 4.0ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277: 1452-5.
26. Djavan B, Fong YK, Ravery V etal. Are repeat biopsies required in men with PSA levels < or =4ng/ml? A Multi-institutional Prospective European Study. Eur. Urol. 2005; 47: 38-44.
27. Djavan B, Zlotta AR, Remzi M etal. Optimal predictors of prostate cancer on repeat biopsy: a prospective study of 1051 men. J. Urol. 2000; 163: 1144-9.
28. Catalona WJ, Partin AW, Slawin KM etal. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542-47.
29. Letran JL, Blase AB, Loberiza FR, Meyer GE, Ransom SD, Brawer MK. Repeat ultrasound guided prostate needle biopsy: use of free to total PSA ratio in predicting prostatic carcinoma. J. Urol. 1998; 60: 426-9.
30. Morgan TO, McLeod DG, Leifer ES, Murphy GP, Moul JW. Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen. Urology 1996; 48: 76-80.
31. Rodríguez-Patrón RR, Mayayo DT, González GA, Zuccarino AL, García GR, Cuesta RC. Can indexes based on PSA determine which patients should undergo repeated ultrasound-guided transrectal prostatic biopsy? Study on 546 patients who underwent repeated biopsy. Arch. Esp. Urol. 2002; 55: 225-34.
32. Benson MC, Whang IS, Pantuck A etal. Prostate-specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J. Urol. 1992; 147: 815-16.
33. Keetch DW, McMurtry JM, Smith DS, Andriole GL, Catalona WJ. Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies. J. Urol. 1996; 156: 428-31.
34. Singh H, Canto EI, Shariat SF etal. Predictors of prostate cancer after initial negative systematic 12 core biopsy. J. Urol. 2004; 171: 1850-4.
35. Okada K, Okihara K, Kitamura K etal. Community-based prostate cancer screening in Japan: predicting factors for positive repeat biopsy. Int. J. Urol. 2010; 17: 541-7.
36. Etzioni RD, Ankerst DP, Weiss NS, Inoue LYT, Thompson IM. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J. Natl. Cancer Inst. 2007; 99: 1510-15.
37. Borboroglu PG, Comer SW, Riffenburgh RH, Amling CL. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J. Urol. 2000; 163: 158-62.
38. Loeb S, Roehl KA, Yu X, Han M, Catalona WJ. Use of prostate-specific antigen velocity to follow up patients with isolated high-grade prostatic intraepithelial neoplasia on prostate biopsy. Urology 2007; 69: 108-12.
39. Vickers AJ, Savage C, O'Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J. Clin. Oncol. 2009; 27: 398-403.
40. Vickers AJ, Wolters T, Savage CJ etal. Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy. J. Urol. 2010; 184: 907-12.
41. Wolters T, Roobol MJ, Bangma CH, Schröder FH. Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? Eur. Urol. 2008; 55: 385-92.
42. Bittner N, Merrick GS, Andreini H etal. Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB. Urology 2009; 74: 171-6.
43. Gann PH, Fought A, Deaton R, Catalona WJ, Vonesh E. Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach. J. Clin. Oncol. 2010; 28: 1714-20.
44. Ramírez ML, Nelson EC, Devere White RW, Lara PN Jr, Evans CP. Current Applications for Prostate-Specific Antigen Doubling Time. Eur. Urol. 2008; 54: 291-300.
45. Shimbo M, Tomioka S, Sasaki M etal. PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer. Jpn J. Clin. Oncol. 2009; 39: 727-31.
46. Garzotto M, Park Y, Mongoue-Tchokote S etal. Recursive partitioning for risk stratification in men undergoing repeat prostate biopsies. Cancer 2005; 104: 1911-17.
47. Epstein J, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J. Urol. 2006; 175: 820-34.
48. O'Dowd GJ, Miller MC, Orozco R, Veltri RW. Analysis of repeated biopsy results within 1year after a non cancer diagnosis. Urology 2000; 55: 553-9.
49. Merrimen JL, Jones G, Walker D, Leung CS, Kapusta LR, Srigley JR. Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. J. Urol. 2009; 182: 485-90.
50. Godoy G, Taneja SS. Contemporary clinical management of isolated high-grade prostatic intraepithelial neoplasia. Prostate Cancer Prostatic Dis. 2008; 11: 20-31.
51. Schoenfield L, Jones JS, Zippe CD etal. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy and the subsequent risk of cancer. BJU Int. 2007; 99: 770-4.
52. Lee MC, Moussa AS, Yu C, Kattan MW, Magi-Galluzzi C, Jones JS. Multifocal high grade prostatic intraepithelial neoplasia is a risk factor for subsequent prostate cancer. J. Urol. 2010; 184: 1958-62.
53. Thompson IM, Lucia MS, Redman MW etal. Finasteride decreases the risk of prostatic intraepithelial neoplasia. J. Urol. 2007; 178: 107-9.
54. Andriole GL, Humphrey P, Ray P etal. Effect of the dual 5-alpha reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J. Urol. 2004; 172: 915-19.
55. Price D, Stein B, Sieber P etal. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. J. Urol. 2006; 176: 965-70.
56. Bostwick DG, Srigley J, Grignon D etal. Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well-differentiated carcinoma. Hum. Pathol. 1993; 24: 819-32.
57. Abouassaly R, Tan N, Moussa A, Jones JS. Risk of prostate cancer after diagnosis of atypical glands suspicious for carcinoma on saturation and traditional biopsies. J. Urol. 2008; 180: 911-14.
58. Zhou M, Magi-Galluzzi C. Clinicopathological features of prostate cancers detected after an initial diagnosis of "atypical glands suspicious for cancer". Pathology 2010; 42: 334-8.
59. Borboroglu PG, Sur RL, Roberts JL, Amling CL. Repeat biopsy strategy in patients with atypical small acinar proliferation or high grade prostatic intraepithelial neoplasia on initial prostate needle biopsy. J. Urol. 2001; 166: 866-70.
60. Scattoni V, Roscigno M, Freschi M etal. Predictors of prostate cancer after initial diagnosis of atypical small acinar proliferation at 10-12 core biopsies. Urology 2005; 66: 1043-7.
61. Mancuso PA, Chabert C, Chin P etal. Prostate cancer detection in men with an initial diagnosis of atypical small acinar proliferation. BJU Int. 2007; 99: 49-52.
62. National Comprehensive Cancer Network. Prostate cancer early detection. In: Kawachi MH, Bahnson RR, Barry M etal. (eds). Clinical Practice Guidelines in Oncology. V.1.2005. National Comprehensive Cancer Network, Jenkintown, PA, 2007; 714-36.
63. Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J. Urol. 2001; 166: 86-91.
64. Jones JS, Oder M, Zippe CD. Saturation prostate biopsy with periprostatic block can be performed in office. J. Urol. 2002; 168: 2108-10.
65. Zaytoun OM, Anil T, Moussa AS, Jianbo L, Fareed K, Jones JS. Morbidity of prostate biopsy after simplified versus complex preparation protocols: assessment of risk factors. Urology 2011; 77: 910-4.
66. Zaytoun OM, Vargo EH, Rajan R, Ryan B, Gordon S, Jones JS. Emergence of fluoroquinolone-resistant escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology 2011; 77: 1035-41.
67. Jones JS. Saturation biopsy for detecting and characterizing prostate cancer. BJU Int. 2007; 99: 1340-44.
68. Ploussard G, Dubosq F, Boublil V etal. Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen. J. Urol. 2009; 182: 1342-9.
69. Pryor MB, Schellhammer PF. The pursuit of prostate cancer in patients with a rising PSA and multiple negative transrectal ultrasound-guided prostate biopsies. Clin. Prostate Cancer 2002; 1: 172-6.
70. Fleshner N, Klotz L. Role of "saturation biopsy" in the detection of prostate cancer among difficult diagnostic cases. Urology 2002; 60: 93-7.
71. de la Taille A, Antiphon P, Salomon L etal. Prospective evaluation of a 21- sample needle biopsy procedure designed to improve the prostate cancer detection rate. Urology 2003; 61: 1181-6.
72. Rabets J, Jones JS, Patel A, Zippe CD. Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. J. Urol. 2004; 172: 94-7.
73. Pinkstaff DM, Igel TC, Petrou SP, Broderick GA, Wehle MJ, Young PR. Systematic transperineal ultrasound guided template biopsy of the prostate: three-year experience. Urology 2005; 65: 735-9.
74. Satoh T, Matsumoto K, Fujita T etal. Cancer core distribution in patients diagnosed by extended transperineal prostate biopsy. Urology 2005; 66: 114-18.
75. Bott SR, Henderson A, Halls JE, Montgomery BS, Laing R, Langley SE. Extensive transperineal template biopsies of prostate: modified technique and results. Urology 2006; 68: 1037-41.
76. Moran BJ, Braccioforte MH, Conterato DJ. Re-biopsy of the prostate using a stereotactic transperineal technique. J. Urol. 2006; 176: 1376-81.
77. Walz J, Graefen M, Chun FK etal. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur. Urol. 2006; 50: 498-505.
78. Pepe P, Aragona F. Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. Urology 2007; 70: 1131-5.
79. Merrick GS, Gutman S, Andreini H etal. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur. Urol. 2007; 52: 715-23.
80. Li H, Yan W, Zhou Y, Ji Z, Chen J. Transperineal ultrasound-guided saturation biopsies using 11-region template of prostate: report of 303 cases. Urology 2007; 70: 1157-61.
81. Sajadi KP, Kim T, Terris MK, Brown JA, Lewis RW. High yield of saturation prostate biopsy for patients with previous negative biopsies and small prostates. Urology 2007; 70: 691-5.
82. Simon J, Kuefer R, Bartsch G Jr, Volkmer BG, Hautmann RE, Gottfried HW. Intensifying the saturation biopsy technique for detecting prostate cancer after previous negative biopsies: a step in the wrong direction. BJU Int. 2008; 102: 459-62.
83. Campos-Fernandes JL, Bastien L, Nicolaiew N etal. Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur. Urol. 2009; 55: 600-9.
84. Novara G, Boscolo-Berto R, Lamon C etal. Detection rate and factors predictive the presence of prostate cancer in patients undergoing ultrasonography-guided transperineal saturation biopsies of the prostate. BJU Int. 2010; 105: 1242-6.
85. Ahyai SA, Isbarn H, Karakiewicz PI etal. The presence of prostate cancer on saturation biopsy can be accurately predicted. BJU Int. 2010; 105: 636-41.
86. Pepe P, Candiano G, Fraggetta F, Galia A, Grasso G, Aragona F. Is transition zone sampling at repeated saturation prostate biopsy still useful? Urol. Int. 2010; 85: 324-7.
87. Djavan B, Ravery V, Zlotta A etal. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J. Urol. 2001; 166: 1679-83.
88. Lopez-Corona E, Ohori M, Scardino PT, Reuter VE, Gonen M, Kattan MW. A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. J. Urol. 2003; 170: 1184-8.
89. Djavan B, Mazal P, Zlotta AR etal. Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the Prospective European Prostate Cancer Detection Study. Prostate 2001; 47: 111-17.
90. Rochester MA, Pashayan N, Matthews F, Doble A, McLoughlin J. Development and validation of risk score for predicting positive repeat prostate biopsy in patients with a previous negative biopsy in a UK population (Abstarct). BMC Urol. 2009; 9: 7.
91. Tan N, Lane BR, Li J, Moussa AS, Soriano M, Jones JS. Prostate Cancers Diagnosed at Repeat Biopsy are Smaller and Less Likely to be High Grade. J. Urol. 2008; 180: 1325-9.
92. Singh H, Canto EI, Shariat SF etal. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J. Urol. 2004; 171: 1089-92.
93. Meng MV, Elkin EP, DuChane J, Carroll PR. Impact of increased number of biopsies on the nature of prostate cancer identified. J. Urol. 2006; 176: 63-9.
94. Taylor JA III, Gancarczyk KJ, Fant GV, Mcleod DG. Increasing the number of core samples taken at prostate needle biopsy enhances the detection of clinically significant prostate cancer. Urology 2002; 60: 841-5.
95. Carroll PR. Early stage prostate cancer - do we have a problem with over-detection, over treatment or both? J. Urol. 2005; 173: 106-2.
96. Jones JS. Prostate cancer: are we over-diagnosing-or under-thinking? Eur. Urol. 2008; 53: 10-12.
97. Erratum: Nomogram for predicting positive repeat prostate biopsy. J Urol 2004; 170 (1):1186-7. J. Urol. 2004; 171: 360-1.
98. Yanke BV, Gonen M, Scardino PT, Kattan MW. Validation of a nomogram for predicting positive repeat biopsy for prostate cancer. J. Urol. 2005; 173: 421-4.
99. Moussa AS, Jones JS, Yu C, Khaled F, Kattan MW. Development and validation of a nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session in the era of extended prostate sampling. BJU Int. 2010; 106: 1309-14.
100. Chun FK, Briganti A, Graefen M etal. Development and external validation of an extended repeat biopsy nomogram. J. Urol. 2007; 177: 510-15.
101. Benecchi L, Pieri AM, Melissari M, Potenzoni M, Pastizzaro CD. A novel nomogram to predict the probability of prostate cancer on repeat biopsy. J. Urol. 2008; 180: 146-9.
102. Stephan C, Cammann H, Bender M etal. Internal validation of an artificial neural network for prostate biopsy outcome. Int. J. Urol. 2010; 17: 62-8.
103. Chun FK, de la Taille A, van Poppel H etal. Prostate cancer gene 3(PCA3): development and internal validation of a novel biopsy nomogram. Eur. Urol. 2009; 56: 659-68.
104. Auprich M, Haese A, Walz J etal. External Validation of Urinary PCA3-Based Nomograms to Individually Predict Prostate Biopsy Outcome. Eur. Urol. 2010; 58: 727-32.
105. Rietbergen JB, Kruger AE, Hoedemaeker RF, Bangma CH, Kirkels WJ, Schröder FH. Repeat screening for prostate cancer after 1-year follow up in 984 biopsied men: clinical and pathological features of detected cancer. J. Urol. 1998; 160: 2121-5.
106. Naughton C, Humphrey PA, Smith D etal. The value of ultrasound determined prostate size in predicting the number of core biopsies needed to detect clinical prostate cancer (abstract). J. Urol. 1997; 157: 64.
107. Scattoni V, Raber M, Abdollah F etal. Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy. Eur. Urol. 2010; 57: 1-8.
108. Ahmed HU, Kirkham A, Arya M etal. Is it time to consider a role for MRI before prostate biopsy? Nat. Rev. Clin. Oncol. 2009; 6: 197-206.
109. Hambrock T, Somford DM, Hoeks C etal. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J. Urol. 2010; 183: 520-7.
110. Lawrentschuk N, Fleshner N. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int. 2009; 103: 730-3.